Clinical Trials · NCT06323161
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 274
- Start date
- Mar 2024
- Locations
- 53 sites, 6 countries
- Primary endpoint
- Change in Glycated Haemoglobin (HbA1c)